Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-07-03, Stock:ABBV, The news for the past five days is as follows:
2018-06-26: NEWS1: AbbVie's (ABBV) Imbruvica sNDA Gets Priority Review From FDA.NEWS2: AbbVie's (ABBV) Imbruvica sNDA Gets Priority Review From FDA.NEWS3: Oversold Conditions For AbbVie (ABBV).NEWS4: Oversold Conditions For AbbVie (ABBV).NEWS5: Google sister company and drug giant chip in another $1 billion to cure age-related diseases.NEWS6: Google sister company and drug giant chip in another $1 billion to cure age-related diseases.NEWS7: Gilead's (GILD) Biktarvy Gets EC Nod for HIV- 1 Infection.NEWS8: Gilead's (GILD) Biktarvy Gets EC Nod for HIV- 1 Infection.NEWS9: AbbVie shares rise on $1 bln investment in partnership with Alphabet-backed health company.NEWS10: See what the IHS Markit Score report has to say about AbbVie Inc..NEWS11: AbbVie and Calico Announce Extension of Groundbreaking Collaboration.NEWS12: AbbVie Extends Collaboration With Alphabet-backed Life Sciences Company Calico.NEWS13: AbbVie Extends Collaboration With Alphabet-backed Life Sciences Company Calico.
2018-06-27: NEWS1: AbbVie (ABBV), Calico Extend R&D Deal, to Invest $500M Each.NEWS2: AbbVie (ABBV), Calico Extend R&D Deal, to Invest $500M Each.NEWS3: [$$] Nike, Facebook, Mitsubishi, and Other Global Picks.NEWS4: AbbVie (ABBV), Calico Extend R&D Deal, to Invest $500M Each.NEWS5: 3 Biotech Stocks With Major Potential Catalysts in July.NEWS6: 3 Biotech Stocks With Major Potential Catalysts in July.NEWS7: 3 Biotech Stocks With Major Potential Catalysts in July.
2018-06-28: NEWS1: Amgen Announces Top-Line Data From Remicade Biosimilar Study.NEWS2: Amgen Announces Top-Line Data From Remicade Biosimilar Study.NEWS3: Healthcare: Drug Pricing Concerns Weigh on Valuations, Creating Opportunities.
2018-06-29: NEWS1: Abbvie, Androgel partner owe $488 million in antitrust case: U.S. judge.NEWS2: Lilly's (LLY) Taltz Positive in Ankylosing Spondylitis Study.NEWS3: Lilly's (LLY) Taltz Positive in Ankylosing Spondylitis Study.NEWS4: Vertex Pops As Rival Disappoints In Cystic Fibrosis And AbbVie Opts Out.NEWS5: Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results.NEWS6: Why Vertex Pharmaceuticals Incorporated Stock Surged 14% Today.NEWS7: Why Vertex Pharmaceuticals Incorporated Stock Surged 14% Today.NEWS8: Why Vertex Pharmaceuticals Incorporated Stock Surged 14% Today.NEWS9: XLV, UNH, MRK, ABBV: Large Outflows Detected at ETF.NEWS10: XLV, UNH, MRK, ABBV: Large Outflows Detected at ETF.NEWS11: Galapagos: Silver Lining to Disappointing Study Data.NEWS12: Bad News Delivers a Decisive Blow to Galapagos N.V..NEWS13: Will a Trade War With China Wreak Havoc in US Healthcare?.NEWS14: Will a Trade War With China Wreak Havoc in US Healthcare?.NEWS15: Should Value Investors Consider AbbVie (ABBV) Stock Now?.NEWS16: Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos.NEWS17: Biotech Stocks Facing FDA Decision In July.NEWS18: Biotech Stocks Facing FDA Decision In July.
2018-07-02: NEWS1: AbbVie Is Out-Trading Its Value — Why It Could Still Be Worth More.NEWS2: Health Care Sector Update for 07/02/2018: SNNA,MRNS,ABBV,PRGO,TEVA,NVS,ADMP.NEWS3: Health Care Sector Update for 07/02/2018: SNNA,MRNS,ABBV,PRGO,TEVA,NVS,ADMP.NEWS4: Health Care Sector Update for 07/02/2018: ABBV,PRGO,TEVA,NVS,ADMP,MRK,AZN.NEWS5: Health Care Sector Update for 07/02/2018: ABBV,PRGO,TEVA,NVS,ADMP,MRK,AZN.NEWS6: Gilead's (GILD) CAR T Therapy Gets Positive CHMP Opinion.NEWS7: Gilead's (GILD) CAR T Therapy Gets Positive CHMP Opinion.NEWS8: Vertex's Shares Rally as a Rival's CF Candidate Disappoints.NEWS9: Vertex's Shares Rally as a Rival's CF Candidate Disappoints.NEWS10: Vertex&apos;s Shares Rally as a Rival&apos;s CF Candidate Disappoints.NEWS11: 7 Favorite Picks of a $40 Billion Portfolio Star.

Answer: Rise